GB0421639D0 - Methods and compositions relating to alzheimer's disease - Google Patents

Methods and compositions relating to alzheimer's disease

Info

Publication number
GB0421639D0
GB0421639D0 GBGB0421639.6A GB0421639A GB0421639D0 GB 0421639 D0 GB0421639 D0 GB 0421639D0 GB 0421639 A GB0421639 A GB 0421639A GB 0421639 D0 GB0421639 D0 GB 0421639D0
Authority
GB
United Kingdom
Prior art keywords
alzheimer
disease
methods
compositions relating
proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0421639.6A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Proteome Sciences PLC
Original Assignee
Proteome Sciences PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proteome Sciences PLC filed Critical Proteome Sciences PLC
Priority to GBGB0421639.6A priority Critical patent/GB0421639D0/en
Publication of GB0421639D0 publication Critical patent/GB0421639D0/en
Priority to AT05788728T priority patent/ATE495445T1/de
Priority to EP10010288.8A priority patent/EP2354795B1/en
Priority to PCT/GB2005/003756 priority patent/WO2006035237A2/en
Priority to US11/664,076 priority patent/US7897361B2/en
Priority to AU2005288689A priority patent/AU2005288689B2/en
Priority to CA2580532A priority patent/CA2580532C/en
Priority to DK10010288.8T priority patent/DK2354795T3/en
Priority to JP2007534083A priority patent/JP5483816B2/ja
Priority to DE602005025897T priority patent/DE602005025897D1/de
Priority to EP12191625A priority patent/EP2562545A1/en
Priority to EP05788728A priority patent/EP1794594B1/en
Priority to US13/005,121 priority patent/US20110165146A1/en
Priority to JP2011128088A priority patent/JP5893269B2/ja
Priority to JP2014159434A priority patent/JP2014209132A/ja
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
GBGB0421639.6A 2004-09-29 2004-09-29 Methods and compositions relating to alzheimer's disease Ceased GB0421639D0 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
GBGB0421639.6A GB0421639D0 (en) 2004-09-29 2004-09-29 Methods and compositions relating to alzheimer's disease
EP05788728A EP1794594B1 (en) 2004-09-29 2005-09-29 Methods and compositions relating to alzheimer's disease
CA2580532A CA2580532C (en) 2004-09-29 2005-09-29 Methods and compositions relating to alzheimer's disease
JP2007534083A JP5483816B2 (ja) 2004-09-29 2005-09-29 アルツハイマー病に関する方法及び組成物
PCT/GB2005/003756 WO2006035237A2 (en) 2004-09-29 2005-09-29 Methods and compositions relating to alzheimer's disease
US11/664,076 US7897361B2 (en) 2004-09-29 2005-09-29 Methods of diagnosing Alzheimer's disease
AU2005288689A AU2005288689B2 (en) 2004-09-29 2005-09-29 Methods and compositions relating to Alzheimer's disease
AT05788728T ATE495445T1 (de) 2004-09-29 2005-09-29 Verfahren und zusammensetzungen in verbindung mit morbus alzheimer
DK10010288.8T DK2354795T3 (en) 2004-09-29 2005-09-29 Methods and compositions relating to Alzheimer's disease
EP10010288.8A EP2354795B1 (en) 2004-09-29 2005-09-29 Methods and compositions relating to Alzheimer`s disease
DE602005025897T DE602005025897D1 (de) 2004-09-29 2005-09-29 Verfahren und zusammensetzungen in verbindung mit morbus alzheimer
EP12191625A EP2562545A1 (en) 2004-09-29 2005-09-29 Methods and compositions relating to Alzheimer's disease
US13/005,121 US20110165146A1 (en) 2004-09-29 2011-01-12 Methods of diagnosing alzheimer's disease
JP2011128088A JP5893269B2 (ja) 2004-09-29 2011-06-08 アルツハイマー病に関する方法及び組成物
JP2014159434A JP2014209132A (ja) 2004-09-29 2014-08-05 アルツハイマー病に関する方法及び組成物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0421639.6A GB0421639D0 (en) 2004-09-29 2004-09-29 Methods and compositions relating to alzheimer's disease

Publications (1)

Publication Number Publication Date
GB0421639D0 true GB0421639D0 (en) 2004-10-27

Family

ID=33397455

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0421639.6A Ceased GB0421639D0 (en) 2004-09-29 2004-09-29 Methods and compositions relating to alzheimer's disease

Country Status (10)

Country Link
US (2) US7897361B2 (https=)
EP (3) EP1794594B1 (https=)
JP (3) JP5483816B2 (https=)
AT (1) ATE495445T1 (https=)
AU (1) AU2005288689B2 (https=)
CA (1) CA2580532C (https=)
DE (1) DE602005025897D1 (https=)
DK (1) DK2354795T3 (https=)
GB (1) GB0421639D0 (https=)
WO (1) WO2006035237A2 (https=)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0421639D0 (en) * 2004-09-29 2004-10-27 Proteome Sciences Plc Methods and compositions relating to alzheimer's disease
GB0426859D0 (en) * 2004-12-07 2005-01-12 Proteome Sciences Plc Diagnosis of neurodegenerative disorders
GB2428240A (en) 2005-07-14 2007-01-24 Univ Gen Ve Diagnostic method for brain damage-related disorders
AU2006291990B2 (en) * 2005-09-13 2012-05-31 National Research Council Of Canada Methods and compositions for modulating tumor cell activity
GB0701626D0 (en) 2007-01-22 2007-03-07 Cambridge Entpr Ltd Methods and biomarkers for diagnosing and monitoring psychotic disorders
AT506819B1 (de) * 2008-06-12 2011-06-15 Affiris Forschungs Und Entwicklungs Gmbh Vakzin zur behandlung von alzheimer-krankheit
EP2344881A4 (en) * 2008-09-26 2012-03-07 Univ Melbourne BIOMARKER FOR MORBUS ALZHEIMER
IT1392551B1 (it) * 2008-11-25 2012-03-09 Bioindustry Park Del Canavese S P A Biomarcatori per la diagnosi e per rilevare la progressione di malattie neurodegenerative, in particolare della sclerosi laterale amiotrofica
JP5755149B2 (ja) * 2009-01-26 2015-07-29 エレクトロフォレティクス リミテッドＥｌｅｃｔｒｏｐｈｏｒｅｔｉｃｓ Ｌｉｍｉｔｅｄ 方法
JP2010271078A (ja) * 2009-05-19 2010-12-02 Mcbi:Kk 認知機能障害疾患を含む精神疾患のバイオマーカーおよび該バイオマーカーを用いた認知機能障害疾患を含む精神疾患の検出方法
CA2709621A1 (en) * 2009-09-11 2011-03-11 Electrophoretics Limited Markers and methods relating to the assessment of alzheimer's disease
CN102666585B (zh) 2009-11-24 2015-02-18 阿莱斯亚生物疗法股份有限公司 抗簇蛋白抗体和抗原结合片段及其减小肿瘤体积的用途
JP6012923B2 (ja) * 2010-12-22 2016-10-25 株式会社Ｍｃｂｉ 認知機能障害疾患のバイオマーカーおよび該バイオマーカーを用いる認知機能障害疾患の検出方法
JP5906519B2 (ja) * 2011-09-13 2016-04-20 国立大学法人 熊本大学 二次元電気泳動による蛋白質の分離方法
EP2780690A4 (en) * 2011-11-18 2015-12-09 Alnylam Pharmaceuticals Inc QUANTIFICATION OF TRANSTHYRETIN AND ITS ISOFORMS
WO2013123588A1 (en) 2012-02-22 2013-08-29 Alethia Biotherapeutics Inc. Co-use of a clusterin inhibitor with an egfr inhibitor to treat cancer
WO2013148166A1 (en) 2012-03-29 2013-10-03 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behlaf Of Arizona State University Nanoscale process to generate reagents selective for individual protein variants
USRE49625E1 (en) 2012-03-29 2023-08-29 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Nanoscale process to generate reagents selective for individual protein variants
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
AU2013243948A1 (en) * 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with human disease
US10501513B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides for the production of oncology-related proteins and peptides
CA2877975C (en) 2012-04-13 2021-09-21 Oasis Diagnostics Corporation Specific salivary biomarkers for risk detection, early diagnosis, prognosis and monitoring of alzheimer's and parkinson's diseases
US9678086B2 (en) 2012-09-10 2017-06-13 The Johns Hopkins University Diagnostic assay for Alzheimer's disease
US9891108B2 (en) 2012-10-03 2018-02-13 The Research Foundation For The State University Of New York Spectroscopic method for Alzheimer's disease diagnosis
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
CA2902068C (en) * 2013-02-28 2023-10-03 Caprion Proteomics Inc. Tuberculosis biomarkers and uses thereof
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
GB201310203D0 (en) 2013-06-07 2013-07-24 Electrophoretics Ltd Materials and methods relating to Alzheimer's disease
GB201310150D0 (en) 2013-06-07 2013-07-24 Electrophoretics Ltd Methods and compositions relating to alzheimer's disease
AU2014311258B2 (en) * 2013-08-27 2020-12-17 Crc For Mental Health Ltd Method of identifying biomarkers of neurological diseases and diagnosis of neurological diseases
GB201322094D0 (en) * 2013-12-13 2014-01-29 Electrophoretics Ltd Methods and compositions relating to alzheimers disease
WO2015103594A1 (en) * 2014-01-06 2015-07-09 Children's Medical Center Corporation Biomarkers for dementia and dementia related neurological disorders
GB201403489D0 (en) * 2014-02-27 2014-04-16 Univ London Queen Mary Biomarkers for endometriosis
WO2016160594A1 (en) * 2015-03-27 2016-10-06 The Research Foundation For The State University Of New York Methods and materials for reducing amyloid beta levels within a mammal
US9904961B2 (en) 2015-05-07 2018-02-27 Kuwait University System and method for determining the feedback capacity of information distributed in a complex network
JP6193942B2 (ja) * 2015-09-09 2017-09-06 株式会社Ｍｃｂｉ 認知機能障害疾患のバイオマーカーおよび該バイオマーカーを用いる認知機能障害疾患の検出方法
CN105403649B (zh) * 2015-12-01 2018-03-20 深圳大学 一种检测ad的尿液多肽组ad生物标记物
JP6947450B2 (ja) * 2016-06-29 2021-10-13 学校法人自治医科大学 バイオマーカー、診断用組成物、及び診断用キット
JP6947451B2 (ja) * 2016-06-29 2021-10-13 学校法人自治医科大学 バイオマーカー、診断用組成物、及び診断用キット
JPWO2019013341A1 (ja) * 2017-07-14 2020-07-09 株式会社Ｍｃｂｉ 疾患検出方法
JP6408087B2 (ja) * 2017-07-25 2018-10-17 株式会社Ｍｃｂｉ 認知機能障害疾患のバイオマーカーおよび該バイオマーカーを用いる認知機能障害疾患の検出方法
AU2018308088B2 (en) 2017-07-25 2025-05-29 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
AU2020214796A1 (en) 2019-01-30 2021-07-29 Truebinding, Inc. Anti-Gal3 antibodies and uses thereof
CN113024651A (zh) * 2019-12-25 2021-06-25 中国医学科学院药物研究所 阿尔茨海默病生物标志物及其应用
WO2021242776A2 (en) 2020-05-26 2021-12-02 Truebinding, Inc. Methods of treating inflammatory diseases by blocking galectin-3
US20220260559A1 (en) * 2020-11-04 2022-08-18 Seer, Inc. Biomarkers for diagnosing alzheimer's disease
CN115808492A (zh) * 2021-09-14 2023-03-17 中国科学院深圳先进技术研究院 一种阿尔兹海默症生物标志物天冬酰胺及其应用
CA3268498A1 (en) * 2022-10-18 2024-04-25 Immungenetics Ag IDENTIFICATION OF A SUBJECT SUFFERING FROM ALZHEIMER'S DISEASE OR PRESENTING A RISK OF DEVELOPING ALZHEIMER'S DISEASE
CN117831756B (zh) * 2024-03-05 2024-06-28 精智未来(广州)智能科技有限公司 一种认知障碍的辅助分析方法、装置、设备及存储介质

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US6342350B1 (en) * 1997-09-05 2002-01-29 The General Hospital Corporation Alpha-2-macroglobulin diagnostic test
US20030211622A1 (en) 1998-06-29 2003-11-13 Roberts L. Jackson Methods and compositions to assess oxidative brain injury
US20030131364A1 (en) 1999-04-27 2003-07-10 Karen Duff Method for producing transgenic animal models with modulated phenotype and animals produced therefrom
JP2001249128A (ja) * 2000-03-06 2001-09-14 Ikagaku:Kk 動脈硬化症またはアルツハイマー病の診断用キット
US20020174447A1 (en) * 2001-01-23 2002-11-21 Greenspan Ralph J. Method for functional mapping of an alzheimer's disease gene network and for identifying therapeutic agents for the treatment of alzheimer's disease
US6528309B2 (en) * 2001-03-19 2003-03-04 The Regents Of The University Of California Vacuum-mediated desiccation protection of cells
US6451547B1 (en) * 2001-04-25 2002-09-17 Syn X Pharma Process for differential diagnosis of Alzheimer's dementia and device therefor
DE10158180A1 (de) * 2001-11-28 2003-09-11 Biovision Ag Verfahren zum Nachweis von Morbus Alzheimer und zur Unterscheidung von Morbus Alzheimer gegenüber anderen demenziellen Erkrankungen, zugehörige Peptide und deren Verwendung
AU2003253014A1 (en) * 2002-06-21 2004-01-06 Innogenetics N.V. Method for the diagnosis and differential diagnosis of neurological diseases
JP2006500920A (ja) * 2002-07-03 2006-01-12 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ 腫瘍老化遺伝子の発現を同定および調節するための試薬および方法
NZ539735A (en) * 2002-10-02 2009-07-31 Dmi Biosciences Inc Diagnosis and monitoring of diseases using markers, such as diketopiperazines
US20060188951A1 (en) * 2003-02-24 2006-08-24 In Hee Mook Method for measuring the level of anti-beta-amyloid antibody in body fluids and diagnostic kit for alzheimer's disease using same
GB0421639D0 (en) * 2004-09-29 2004-10-27 Proteome Sciences Plc Methods and compositions relating to alzheimer's disease

Also Published As

Publication number Publication date
US20110165146A1 (en) 2011-07-07
JP2011209291A (ja) 2011-10-20
WO2006035237A3 (en) 2006-08-03
JP2014209132A (ja) 2014-11-06
EP2354795B1 (en) 2014-12-17
ATE495445T1 (de) 2011-01-15
WO2006035237A2 (en) 2006-04-06
JP5483816B2 (ja) 2014-05-07
DE602005025897D1 (de) 2011-02-24
DK2354795T3 (en) 2015-02-16
JP5893269B2 (ja) 2016-03-23
EP1794594A2 (en) 2007-06-13
CA2580532C (en) 2019-06-25
EP1794594B1 (en) 2011-01-12
EP2562545A1 (en) 2013-02-27
AU2005288689A1 (en) 2006-04-06
AU2005288689B2 (en) 2011-10-27
US20080070995A1 (en) 2008-03-20
JP2008514946A (ja) 2008-05-08
US7897361B2 (en) 2011-03-01
CA2580532A1 (en) 2006-04-06
EP2354795A1 (en) 2011-08-10

Similar Documents

Publication Publication Date Title
GB0421639D0 (en) Methods and compositions relating to alzheimer's disease
SI1594833T1 (sl) Derivati 1-fenilalkankarboksilne kisline za zdravljenje nevrodegenerativnih bolezni
WO2005032471A3 (en) Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
WO2009149486A3 (en) Compounds for treating beta-amyloidoses
EP1765388B8 (de) Kombinationstherapie zur vorbeugung oder behandlung der alzheimerschen erkrankung sowie set hierfür
TWI340640B (en) Combination, kit and pharmaceutical composition for treatment of parkinson's disease
MX2008009947A (es) Composiciones farmaceuticas que comprenden dextrometorfano y quinidina para el tratamiento de depresion, ansiedad y trastornos neurodegenerativos.
SI2527315T1 (sl) Spojine, sestavki in metode za zdravljenje amiloidnih bolezni in sinukleinopatij, kot so Alzheimerjeva bolezen, diabetes tipa 2 in Parkinsonova bolezen
WO2004062625A3 (en) Macrocyclic beta-secretase inhibitors for treatment of alzheimer's disease
WO2005004803A3 (en) Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer's disease
WO2004092405A3 (en) Juvenile hemochromatosis gene (hfe2a), expression products and uses thereof
WO2005051914A8 (en) Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
IL159527A0 (en) Human dr4 antibodies and uses thereof
WO2005018545A3 (en) Macrocyclic beta-secretase inhibitors for the treatment of alzheimer's disease
MY162640A (en) Thioninium compounds and their use
IL177787A0 (en) 1-aminovyclohexane derivatives for the treatment of agitation and other behavioral disorders, especially those associated with alzheimer's disease
WO2006078576A3 (en) Aminomethyl beta-secretase inhibitors for the treatment of alzheimer's disease
AU2003238046A1 (en) Substituted 3- and 4- aminomethylpiperidines for use as beta-secretase in the treatment of alzheimer's disease
WO2007058862A3 (en) Imidazolidinone compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease
IL184849A0 (en) Organic compounds useful for the treatment of alzheimer's disease, their use and method of preparation
ATE480243T1 (de) Zusammensetzung zur verwendung bei diagnose der akuten verletzungen des zentralen nervensystems
PL1612210T3 (pl) Nowe analogi nitrobenzylotioinozyny
WO2007026254A3 (en) Benzodiazepine derivatives , their preparation and the therapeutic use thereof
WO2007048034A3 (en) Use of androgens for the treatment of parkinson' s disease
WO2007019080A3 (en) Tricyclic beta-secretase inhibitors for the treatment of alzheimer's disease

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)